Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder
Overactive Bladder
Related content
RECOMMENDED
Uro-Oncology
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies
★ 2
Recommended by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol.
Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, Montironi R, Giannatempo P, Farè E, Pederzoli F, Bandini M, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Dehò F, Ali SM, Chung JH, Ross JS, Salonia A, Briganti A, Montorsi F
doi: 10.1016/j.eururo.2019.10.026.
Overactive BladderUro-Oncology
Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients
Eur Urol.
Bosschieter J, Nieuwenhuijzen JA, van Ginkel T, Vis AN, Witte B, Newling D, Beckers GMA, van Moorselaar RJ
doi: 10.1016/j.eururo.2017.06.038.
Overactive BladderUro-Oncology
Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer
Mayo Clin Proc.
Giridhar KV, Kohli M
doi: 10.1016/
Overactive BladderUro-Oncology
An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups
Urol Oncol.
Bosschieter J, Nieuwenhuijzen JA, Vis AN, van Ginkel T, Lissenberg-Witte BI, Beckers GMA, van Moorselaar RJA
doi: 10.1016/j.urolonc.2018.05.026.
Uro-Oncology
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update
Eur Urol.
Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, Zigeuner R, Capoun O, Cohen D, Escrig JLD, Hernández V, Peyronnet B, Seisen T, Soukup V
doi: 10.1016/j.eururo.2019.08.016.
Further Publications Urology
Optimal Pathologic Response After Neoadjuvant Chemotherapy For Muscle-Invasive Bladder Cancer: Results From A Global, Multi-Center Collaboration
BJU Int
Ravi P, Pond GR, Diamantopoulos LN, Su C, Alva A, Jain RK, Skelton WP, Gupta S, Tward JD, Olson KM, Singh P, Grunewald CM, Niegisch G, Lee JL, Gallina A, Bandini M, Necchi A, Mossanen M, McGregor BA, Curran C, Grivas P, Sonpavde GP
doi: 10.1111/bju.15434
Uro-Oncology
No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study
World J Urol.
Jerlström T, Chen R, Liedberg F, Andrén O, Ströck V, Aljabery FAS, Hosseini A, Sherif A, Malmström PU, Ullén A, Gårdmark T, Fall K
doi: 10.1007/s00345-019-02770-2
Uro-Oncology
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma
BJU Int.
D'Andrea D, Matin S, Black PC, Petros FG, Zargar H, Dinney CP, Cookson MS, Kassouf W, Dall'Era MA, McGrath JS, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, Sridhar SS, North S, Barocas DA, Lotan Y, Stephenson AJ, van Rhijn BW, Spiess PE, Daneshmand S, Shariat SF
doi: 10.1111/bju.15253.
Uro-Oncology
Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection
Eur Urol.
Del Giudice F, Barchetti G, De Berardinis E, Pecoraro M, Salvo V, Simone G, Sciarra A, Leonardo C, Gallucci M, Catalano C, Catto JWF, Panebianco V
doi: 10.1016/j.eururo.2019.09.029.